Restricted accessResearch articleFirst published online 2013-04
Tubulin Beta Chain,Filamin A Alpha Isoform 1,and Cytochrome b-c1 Complex Subunit 1 As Serological Diagnostic Biomarkers of Esophageal Squamous Cell Carcinoma: A Proteomics Study
Despite the major advances in diagnosis and treatment, esophageal squamous cell carcinoma (ESCC) remains a major life-threatening disease. Early diagnosis is critical for guiding the therapeutic management of ESCC. This case-control study focused on the proteomic analysis of serum of healthy volunteers and ESCC patients using the ClinProt profiling technology based on mass spectrometry. A total of 80 healthy volunteers and 119 ESCC patients were enrolled. We identified a pattern of proteins/peptides (including m/z 1867, 2700, and 2094) and differentiated ESCC patients from healthy volunteers with sensitivity and specificity close to 100%. Using mass spectrometry (LTQ orbitrap XL), tubulin beta chain, filamin A alpha isoform 1, and cytochrome b-c1 complex subunit 1 were identified as the three differentially expressed proteins/peptides in the patient serum. These three dysregulated proteins/peptides could be involved in the pathogenesis of ESCC and may serve as putative serological diagnostic biomarkers of ESCC. We suggest that further proteomics and multi-omics research are warranted to identify novel post-genomics diagnostics that can in the future pave the way for personalized medicine for patients with ESCC, a cancer for which we currently lack an integrated battery of diagnostics in the field of oncology.
Get full access to this article
View all access options for this article.
References
1.
AlperO, Stetler-StevensonWG, HarrisLNet al.2009. Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci, 100:1748–1756.
2.
ArianmaneshM, McIntoshRH, LeaRG, FowlerPA, Al-GuboryKH. 2011. Ovine corpus luteum proteins, with functions including oxidative stress and lipid metabolism, show complex alterations during implantation. J Endocrinol, 210:47–58.
3.
BedollaRG, WangY, AsuncionAet al.2009. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: Immunohistochemical correlation with metastases. Clin Cancer Res, 15:788–796.
4.
BourasG, NakanishiT, FujitaY, TsunemiS, TakuboT, TanigawaN. 2012. Identification of beta-tubulin as a common immunogen in gastrointestinal malignancy by mass spectrometry of colorectal cancer proteome: Implications for early disease detection. Anal Bioanal Chem, 403:1801–1809.
5.
BryanJ, WilsonL. 1971. Are cytoplasmic microtubules heteropolymers?Proc Natl Acad Sci USA, 68:1762–1766.
6.
DalyJM, FryWA, LittleAGet al.2000. Esophageal cancer: Results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg, 190:562–572discussion 572–563.
7.
DumontetC, JordanMA. 2010. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov, 9:790–803.
8.
EbertMP, RockenC. 2006. Molecular screening of gastric cancer by proteome analysis. Eur J Gastroenterol Hepatol, 18:847–853.
9.
EdgeSB, ComptonCC. 2010. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17:1471–1474.
10.
FanNJ, GaoCF, WangCSet al.2012a. Discovery and verification of gelsolin as a potential biomarker of colorectal adenocarcinoma in the Chinese population: Examining differential protein expression using an iTRAQ labelling-based proteomics approach. Can J Gastroenterol, 26:41–47.
11.
FanNJ, GaoCF, WangXL. 2011. Identification of regional lymph node involvement of colorectal cancer by serum SELDI proteomic patterns. Gastroenterol Res Pract, 2011; 784967.
12.
FanNJ, GaoCF, ZhaoG, WangXL, LiuQY. 2012b. Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis. Diagn Pathol, 7:45.
13.
FanNJ, GaoCF, ZhaoG, WangXL, QiaoL. 2012c. Serum peptidome patterns for early screening of esophageal squamous cell carcinoma. Biotechnol Appl Biochem, 59:276–282.
14.
FanNJ, GaoCF, WangCSet al.2012. Identification of the up-regulation of TP-alpha, collagen alpha-1(VI) chain, and S100A9 in esophageal squamous cell carcinoma by a proteomic method. J Proteom, 75:3977–3986.
15.
GabelliniN. 1988. Organization and structure of the genes for the cytochrome b/c1 complex in purple photosynthetic bacteria. A phylogenetic study describing the homology of the b/c1 subunits between prokaryotes, mitochondria, and chloroplasts. J Bioenerg Biomembr, 20:59–83.
16.
HartwigJH, StosselTP. 1975. Isolation and properties of actin, myosin, and a new actin binding protein in rabbit alveolar macrophages. J Biol Chem, 250:5696–5705.
17.
HolmesRS, VaughanTL. 2007. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol, 17:2–9.
18.
HudlerP, GorsicM, KomelR. 2010. Proteomic strategies and challenges in tumor metastasis research. Clin Exp Metastasis, 27:441–451.
19.
IizukaT, IsonoK, KakegawaT, WatanabeH. 1989. Parameters linked to ten-year survival in Japan of resected esophageal carcinoma. Japanese Committee for Registration of Esophageal Carcinoma Cases. Chest, 96:1005–1011.
JemalA, BrayF, CenterMM, FerlayJ, WardE, FormanD. 2011. Global cancer statistics. CA Cancer J Clin, 61:69–90.
22.
KashyapMK, HarshaHC, RenuseSet al.2010. SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome. Cancer Biol Ther, 10:796–810.
23.
KavallarisM. 2010. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer, 10:194–204.
24.
KellyP, AppleyardV, MurrayKet al.2010. Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br J Cancer, 103:232–238.
25.
KeshamouniVG, MichailidisG, GrassoCSet al.2006. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res, 5:1143–1154.
26.
KetterlinusR, HsiehSY, TengSH, LeeH, PuschW. 2005. Fishing for biomarkers: Analyzing mass spectrometry data with the new ClinProTools software. BiotechniquesSuppl:37–40.
27.
KilpatrickLA, LabusJS, CoveleskieKet al.2011. The HTR3A polymorphism c. −42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome. Gastroenterology, 140:1943–1951.
28.
LiC, XinW, SyMS. 2010. Binding of pro-prion to filamin A: By design or an unfortunate blunder. Oncogene, 29:5329–5345.
29.
LinHB, CadeteVJ, SawickaJ, WozniakM, SawickiG. 2012. Effect of the myosin light chain kinase inhibitor ML-7 on the proteome of hearts subjected to ischemia-reperfusion injury. J Proteom, 75:5386–5395.
30.
LiuLH, ShanBE, TianZQet al.2010. Potential biomarkers for esophageal carcinoma detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem Lab Med, 48:855–861.
31.
NakamuraF, StosselTP, HartwigJH. 2011. The filamins: Organizers of cell structure and function. Cell Adh Migr, 5:160–169.
32.
PanC, HeN, ZhaoMet al.2011. Subdividing the M1 stage of liver metastasis for nasopharyngeal carcinoma to better predict metastatic survival. Med Oncol, 28:1349–1355.
33.
PawarH, KashyapMK, SahasrabuddheNAet al.2011. Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biol Ther, 12:510–522.
34.
PerezEA. 2009. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther, 8:2086–2095.
35.
QasimM, RahmanH, OellerichM, AsifAR. 2011. Differential proteome analysis of human embryonic kidney cell line (HEK-293) following mycophenolic acid treatment. Proteome Sci, 9:57.
36.
SinghPK, BrandRE, MehlaK. 2012. MicroRNAs in pancreatic cancer metabolism. Nat Rev Gastroenterol Hepatol, 9:334–344.
37.
SwetsJA. 1988. Measuring the accuracy of diagnostic systems. Science, 240:1285–1293.
38.
TangW, ShiYQ, ZouJJet al.2011. Serum biomarker of diabetic peripheral neuropathy indentified by differential proteomics. Front Biosci, 16:2671–2681.
39.
TribouletJP, MarietteC, ChevalierD, AmrouniH. 2001. Surgical management of carcinoma of the hypopharynx and cervical esophagus: Analysis of 209 cases. Arch Surg, 136:1164–1170.
40.
UhlenM, BjorlingE, AgatonCet al.2005. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteom, 4:1920–1932.
41.
WulfkuhleJD, LiottaLA, PetricoinEF. 2003. Proteomic applications for the early detection of cancer. Nat Rev Cancer, 3:267–275.
42.
YehIT, LuduenaRF. 2004. The betaII isotype of tubulin is present in the cell nuclei of a variety of cancers. Cell Motil Cytoskeleton, 57:96–106.
43.
YueJ, WangQ, LuH, BrennemanM, FanF, ShenZ. 2009. The cytoskeleton protein filamin-A is required for an efficient recombinational DNA double strand break repair. Cancer Res, 69:7978–7985.
44.
ZetheliusB, BerglundL, SundstromJet al.2008. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med, 358:2107–2116.
45.
ZhangJ, WangK, LiuSS, DaiL, ZhangJY. 2011. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res, 10:2863–2872.
